Allogeneic osteoblastic cell therapy - Bone Therapeutics

Drug Profile

Allogeneic osteoblastic cell therapy - Bone Therapeutics

Alternative Names: ALLOB; ALLOB implantation

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bone Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta; Osteonecrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fracture; Intervertebral disc degeneration

Most Recent Events

  • 20 Sep 2017 Bone Therapeutics completes the phase II ALLOB-MF1 trial in Fracture treatment in Belgium and Germany (Intraosseous) (EudraCT2015-000650-38)
  • 20 Sep 2017 Interim adverse events and efficacy data from a phase I/IIa trial in Fracture treatment, which met its primary endpoint, released by Bone Therapeutics
  • 20 Sep 2017 Bone Therapeutics terminates enrolment in a phase I/IIa trial in Fracture treatment in Belgium and Germany due to early positive results (NCT02020590)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top